CN Stock MarketDetailed Quotes

688238 Obio Technology

Watchlist
  • 5.66
  • +0.24+4.43%
Market Closed Apr 29 15:00 CST
3.67BMarket Cap-10.82P/E (TTM)

About Obio Technology Company

The company was founded in 2013. Adhering to the concept of “integrating your resources and serving life sciences”, the company adheres to the values of “customer first, efficient execution, pursuit of excellence, innovation and breakthrough, honesty and pragmatism”, and promotes cell and gene therapy from research to clinical practice in all aspects. The company is a biotechnology company focusing on cell and gene therapy technology services, focusing on providing CRO services such as gene therapy vector development, gene function research, drug targets and pharmacodynamics research for basic cell and gene therapy research; providing CDMO services such as process development and testing, IND-CMC pharmaceutical research, GMP production of clinical samples and commercial products; and providing technical services such as cell preparation, recombinant protein/exosome production and cell storage for the field of regenerative medicine and anti-aging. Main products: Biologics products, reagents, kits and other products.

Company Profile

Short Name-A和元生物
Company NameObio Technology (Shanghai) Corp., Ltd.
Listing DateMar 22, 2022
Issue Price13.23
Shares Offered100.00M share(s)
FoundedMar 5, 2013
Chairmanoudong pan
Legal Representativeoudong pan
General Manageroudong pan
Secretaryluyuan xu
Employees692
ProvinceShang Hai Shi
Phone021-58180909
Office AddressBuilding 19, Lane 908, Ziping Road, Pudong District, Shanghai
Zip Code201321
Registered AddressBuilding 19, Lane 908, Ziping Road, Pudong International Medical Park, Shanghai
Fax021-55230588
Emailzhengquanbu@obiosh.com
Business License913100000625940784
BusinessThe issuer is a biotechnology company focusing on the field of gene therapy, focusing on providing integrated CRO/CDMO services such as gene therapy vector construction, target and efficacy research, process development and testing, IND-CMC pharmaceutical research, clinical phase I-III, and commercial GMP production for pioneering research and drug development for gene therapy such as recombinant viral vector products, oncolytic virus products, and CAR-T products.

Company Executives

  • Name
  • Position
  • Salary
  • oudong pan
  • Chairman, Directors
  • 1.06M
  • shan yin
  • Directors, Deputy General Manager
  • 673.20K
  • junyi pan
  • Directors
  • 600.60K
  • fujie wang
  • Directors, Deputy General Manager
  • 664.20K
  • gang wang
  • Independent Directors
  • 100.00K
  • zhengqi song
  • Independent Directors
  • 100.00K
  • lining gan
  • Independent Directors
  • 100.00K
  • luyuan xu
  • Board Secretary, Deputy General Manager, Head of Finance
  • 979.80K
  • wen zhao
  • Securities Affairs Representative
  • --
  • xiao gao
  • Auditors
  • --
  • qinbin wu
  • Deputy General Manager
  • 1.44M
  • qingmei xia
  • Deputy General Manager
  • 706.90K
  • suli liu
  • Core Technical Personnel
  • 186.60K
  • jiali yang
  • Core Technical Personnel
  • 377.40K
  • xinglin yang
  • Core Technical Personnel
  • 513.60K
  • haizi cheng
  • Core Technical Personnel
  • --
  • sijie song
  • Employee Supervisors
  • 156.60K
  • rong ma
  • Employee Supervisors
  • 448.80K